This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $870,467 to Ension Inc. to develop a bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications. The goal is to extend the operating range of the bearingless motor to accommodate the high pressure and low flow requirements for neonates and infants weighing 5-15 kg. The deliverables include a multifunctional, advanced compact ECLS (extracorporeal life support) system incorporating this innovative bearingless motor technology. This 24-month award, running from February 1, 2025 to January 31, 2027, represents the final phase of development for this pediatric cardiopulmonary assist system.
Generated 3/4/25, 7:28 AM